

Unaudited Condensed Interim Consolidated Financial Statements

Second Quarter
For the Six-Month Period Ended June 30, 2023

Under National Instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the interim financial statements, then such financial statements must be accompanied by a notice to this effect. Management of Ucore Rare Metals Inc. has prepared these condensed interim consolidated financial statements. Management has compiled the unaudited condensed interim consolidated statement of financial position of Ucore Rare Metals Inc. as at June 30, 2023, the audited condensed consolidated statement of financial position as at December 31, 2022 and the unaudited condensed interim consolidated statements of comprehensive loss, changes in shareholder's equity and cash flows for the six-month period ended June 30, 2023 and June 30, 2022. The Company's independent auditors have not audited, reviewed or otherwise attempted to verify the accuracy or completeness of the June 30, 2023 condensed interim consolidated financial statements. Readers are cautioned that these statements may not be appropriate for their intended purposes.

Condensed Interim Consolidated Statements of Financial Position Expressed in Canadian dollars (Unaudited - Prepared by Management)

	June 30, 2023	December 31, 2022
	\$	\$
ASSETS		
Current assets		
Cash	281,104	2,261,981
Marketable securities	750	1,500
Receivables (note 6)	461,247	433,511
Prepaid expenses and other	343,979	235,568
Deferred financing fee (note 12)	257,356	
	1,344,436	2,932,560
Other asset	67,829	69,328
Plant and equipment (note 7)	4,937,015	2,402,431
Right-of-use asset (note 8)	29,555	73,887
Intellectual property (note 9)	8,089,154	8,089,154
Resource properties and related exploration costs (note 10)	39,261,948	39,673,847
	53,729,937	53,241,207
LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities		
Accounts payable and accrued liabilities	2,861,340	1,490,357
Lease liability (note 11)	36,205	87,250
Convertible debentures (note 13)	1,355,783	1,256,689
Loan payable (note 12)	2,792,501	-
	7,045,829	2,834,296
Long-term liabilities		
Loan payable (note 12)	962,455	2,184,515
	8,008,284	5,018,811
Shareholders' equity		
Share capital (note 14)	86,700,123	86,693,212
Contributed surplus (note 14)	27,179,656	25,781,314
Warrants (note 14)	4,675,747	4,951,382
Accumulated other comprehensive income	5,065,599	5,591,099
Deficit	(77,899,472)	(74,794,611)
	45,721,653	48,222,396
	53,729,937	53,241,207

Going concern (note 2) Contingency (note 18) Subsequent events (note 19)

Approved on behalf of the Board of Directors

(s) Patrick Ryan
Patrick Ryan, CEO and Director
Geoff Clarke, Director

Condensed Interim Consolidated Statements of Loss and Comprehensive Loss Expressed in Canadian dollars

(Unaudited - Prepared by Management)

	For the Three Months		For the Six I	Months
	Ended Jui	ne 30	Ended Jur	ne 30
	2023	2022	2023	2022
	\$	\$	\$	\$
EXPENSES				
Amortization	23,792	23,936	47,583	57,002
Investor relations and marketing	145,464	89,298	277,998	152,773
Office and premises	72,132	53,733	127,353	121,284
Professional services	258,341	195,886	408,743	360,783
Salaries and consultants	295,629	349,543	608,028	869,096
Securities and regulatory	37,521	40,654	60,687	53,717
Research and development, net (note 6)	5,570	244,523	76,666	432,103
Share-based payments (note 14)	470,123	(2,121)	761,860	111,452
Travel	83,251	38,427	169,229	56,223
	1,391,823	1,033,879	2,538,147	2,214,433
OTHER INCOME (EXPENSES)				
Interest income	-	-	5,031	126
Interest and accretion expense	(300,278)	(110,321)	(531,422)	(217,927)
Fair value adjustment of derivative liabilities (note 13)	75,271	202,570	(187,992)	179,925
Financing fee (note 12)	(72,731)	-	(72,731)	-
Gain on extension of convertible debentures (note 13)	167,574	-	167,574	-
Foreign exchange gain (loss)	57,086	(33,958)	52,826	(17,215)
	(73,078)	58,291	(566,714)	(55,091)
NET LOSS	(1,464,901)	(975,588)	(3,104,861)	(2,269,524)
Net Loss per share - basic and diluted	(0.03)	(0.02)	(0.06)	(0.05)
Weighted average number of basic and diluted common shares	56,140,366	49,084,130	56,140,366	49,084,130
COMPREHENSIVE LOSS:				
Net loss for the period	(1,464,901)	(975,588)	(3,104,861)	(2,269,524)
Items which may be subsequently recycled through	(1,101,001)	(0.0,000)	(0,101,001)	(2,200,02)
profit or loss				
Foreign currency translation difference arising on				
translation of foreign subsidiaries	(511,547)	699,894	(524,750)	351,387
Unrealized gain (loss) on available-for-sale securities	(250)	(250)	(750)	250
	(1,976,698)	(275,944)	(3,630,361)	(1,917,887)

Condensed Interim Consolidated Statements of Changes in Equity Expressed in Canadian dollars (Unaudited - Prepared by Management)

	Number of Shares	Share Capital	(Contributed Surplus	Warrants	Co	Other omprehensive acome (Loss)	Deficit	Total Equity
Balance at January 1, 2022	49,084,130	\$ 84,252,990	\$	24,033,093	\$ 3,178,387	\$	3,888,978 \$	(69,325,696)	\$ 46,027,752
Net loss Unrealized gain (loss) on available for sale securities	-	-			-		- 250	(2,269,524)	(2,269,524) 250
Foreign currency translation adjustment	-	-		<u>-</u>	-		351.387	<u>-</u>	351,387
Expiry of warrants	-	-		431,828	(431,828)		-	-	-
Share-based payments	-	-		111,452	-		-	-	111,452
Balance at June 30, 2022	49,084,130	\$ 84,252,990	\$	24,576,373	\$ 2,746,559	\$	4,240,615 \$	(71,595,220)	\$ 44,221,317
Balance at January 1, 2023	56,139,925	\$ 86,693,212	\$	25,781,314	\$ 4,951,382	\$	5,591,099 \$	(74,794,611)	\$ 48,222,396
Net loss	-	-		-	-		-	(3,104,861)	(3,104,861)
Unrealized gain (loss) on available for sale securities	-	-		-	-		(750)	-	(750)
Shares issued on the exercise of warrants (note 14)	7,000	6,911		-	(2,361)		-	-	4,550
Issuance of warrants (note 12)	-	-		-	330,087		-	-	330,087
Foreign currency translation adjustment	-	-		-	-		(524,750)	-	(524,750)
Expiry of warrants (note 14)	-	-		603,361	(603,361)		-	-	
Share-based payments (note 14)	-	-		794,981	-		-	-	794,981
Balance at June 30, 2023	56,146,925	\$ 86,700,123	\$	27,179,656	\$ 4,675,747	\$	5,065,599 \$	(77,899,472)	\$ 45,721,653

Condensed Interim Consolidated Statements of Cash Flows Expressed in Canadian dollars For the six-month period ended June 30 (Unaudited - Prepared by Management)

CASH FLOWS USED IN OPERATING ACTIVITIES Net loss for the period (3,104,861) (2,269,524) Adjustments and items not involving cash: Amortization 47,583 57,002 Amortization recorded in research and development 11,141 15,229
Net loss for the period (3,104,861) (2,269,524) Adjustments and items not involving cash: Amortization 47,583 57,002 Amortization recorded in research and development 11,141 15,229
Net loss for the period (3,104,861) (2,269,524) Adjustments and items not involving cash: Amortization 47,583 57,002 Amortization recorded in research and development 11,141 15,229
Adjustments and items not involving cash: Amortization Amortization recorded in research and development 47,583 57,002 11,141 15,229
Amortization 47,583 57,002 Amortization recorded in research and development 11,141 15,229
Amortization recorded in research and development 11,141 15,229
·
Change in fair value of derivative liability (note 13) 187,992 (179,925)
Financing fee (note 12) 72,731 -
Gain on extension of convertible debentures (note 13) (167,574)
Share-based payments (note 14) 761,860 111,452
Interest and accretion expense 379,549 115,191
Unrealized foreign exchange (gain) loss (68,937) 15,891
(1,880,516) (2,134,684)
Change in non-cash operating working capital:
Receivables 273,577 (117,088)
Prepaid expenses and other (33,064) 83,004
Accounts payable and accrued liabilities 475,212 (100,328)
Cash flow used in operating activities (1,164,791) (2,269,096)
CASH FLOWS FROM (USED) IN FINANCING ACTIVITIES
· · ·
Repayment of lease liabilities (note 11) (51,045) (43,976)
Proceeds from loans payable (note 12) 1,345,005 -
Proceeds from the exercise of warrants (note 14) 4,550 - 4,004,000 (55,005)
Cash flows from (used) in financing activities 1,294,230 (55,325)
CASH FLOWS USED IN INVESTING ACTIVITIES
Purchase of plant and equipment (1,901,857) (63,303)
Additions to other asset - (8,986)
Additions to resource properties and related exploration costs (207,741) (223,082)
Cash flows used in investing activities (2,109,598) (295,371)
<u></u>
DECREASE IN CASH (1,980,159) (2,619,792)
Foreign exchange impact on cash (718) 1,225
CASH, beginning of period 2,261,981 3,331,164
CASH, end of period 281,104 712,597
201,104

Supplementary Cash Flow Information (note 17)

1. NATURE OF OPERATIONS

Ucore Rare Metals Inc. ("Ucore" or the "Company") is a corporation domiciled in Canada. The address of the Company's head office is 210 Waterfront Drive, Suite 106, Halifax N.S., B4A 0H3. The Company is focused on rare and critical metal resources, extraction, beneficiation, and separation technologies with the potential for production, growth and scalability. The Company has an effective 100-per-cent ownership stake in the Bokan-Dotson Ridge rare earth element project in southeast Alaska, United States (see note 10). The Company's vision and plan is to become a leading advanced technology company, providing best-in-class metal separation products and services to the mining and mineral extraction industry. To date, the Company has not earned significant revenues and is considered to be a development stage enterprise.

On May 8, 2020, the Company acquired 100% of the issued and outstanding shares of Innovation Metals Corp. ("IMC"), the developer of its proprietary RapidSXTM process for the low-cost separation and purification of rare earth elements ("REEs"), nickel ("Ni"), cobalt ("Co"), lithium ("Li") and other technology metals, via an accelerated form of solvent extraction. IMC is commercializing this approach for a number of metals, to help enable mining and metal-recycling companies to compete in today's global marketplace.

2. GOING CONCERN

These condensed interim consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") applicable to a going concern, which assumes the Company will continue in operation for the foreseeable future and be able to realize its assets and discharge its liabilities and commitments in the normal course of business. In assessing whether the going concern assumption is appropriate, management takes into account all available information about the future, which is at least, but is not limited to, twelve months from the end of the reporting period. Management is aware, in making its assessment, of material uncertainties related to events or conditions that may cast significant doubt upon the Company's ability to continue as a going concern, as described in the following paragraphs.

The Company has no sources of revenue, experienced significant losses and negative cash flows from operations in 2023 and 2022 and has a deficit. Subsequent to June 30, 2023, the Company closed a private placement of units for gross proceeds of \$4,409,500, as further described in note 19. Without additional financing or other satisfactory arrangements, the Company's financial resources will not be sufficient to develop its projects and continue the advancement of the Company's RapidSXTM technology. The ability of the Company to continue as a going concern, realize its assets and discharge its liabilities in the normal course of business, expand upon its exploration and development programs, and advance the Company's RapidSXTM technology is contingent upon securing financing or monetizing assets. The timing and availability of additional financing will be determined largely by market conditions, the results of the Company's ongoing exploration and development programs, and the advancement of Company's RapidSXTM technology. There is no certainty that the Company will be able to raise funds as they are required in the future.

These financial statements do not reflect adjustments that would be necessary if the going concern assumption were not appropriate. If the going concern basis was not appropriate for these financial statements, then adjustments would be necessary to the carrying value of assets and liabilities, the reported revenues and expenses, and the statement of financial position classifications used.

3. BASIS OF PRESENTATION

Statement of compliance

These condensed interim consolidated financial statements have been prepared in accordance with IFRS applicable to the preparation of interim financial statements, including IAS 34 *Interim Financial Reporting*.

The date the Board of Directors approved the financial statements is August 28, 2023.

Basis of measurement

These condensed interim consolidated financial statements have been prepared using the historical cost basis except for certain financial instruments that have been measured at fair value. All intercompany transactions, balances, and expenses are eliminated on consolidation.



3. BASIS OF PRESENTATION (continued)

Items included in the financial statements of each of the Company's subsidiaries are measured using the currency of the primary economic environment in which the entity operates ("functional currency"). The condensed interim consolidated financial statements are presented in Canadian dollars, which is the functional and presentation currency of the Company.

Use of estimates and judgments

The preparation of financial statements requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. These estimates are based on historical experience, current and future economic conditions, and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The determination of estimates requires the exercise of judgments based on various assumptions and other factors such as historical experience and current and expected economic conditions. Actual results could differ from those estimates.

The use of estimates and judgments are the same as those applied in the Company's consolidated financial statements as at and for the year ended December 31, 2022.

4. ACCOUNTING POLICIES, CHANGES AND RECENT PRONOUNCEMENTS

The accounting policies applied in these condensed interim consolidated financial statements are the same as those applied in the Company's consolidated financial statements as at and for the year ended December 31, 2022.

The Company adopted the following accounting standards and amendments to accounting standards effective January 1, 2023:

IAS 1 – Presentation of Financial Statements

On January 23, 2020, the IASB issued an amendment to IAS 1 Presentation of Financial Statements providing a more general approach to the classification of liabilities. The amendment clarifies that the classification of liabilities as current or noncurrent depends on the rights existing at the end of the reporting period as opposed to the expectations of exercising the right for settlement of the liability. The amendments further clarify that settlement refers to the transfer of cash, equity instruments, other assets, or services to the counterparty. The amendments are effective for annual periods beginning on or after January 1, 2023 and are to be applied retrospectively, with early adoption permitted. These amendments had no impact on the Company's condensed interim consolidated financial statements.

5. CAPITAL MANAGEMENT

The Company's capital as at June 30, 2023 consists of shareholders' equity of \$45,721,653 (December 31, 2022 - \$48,222,396). The Company's objective when managing capital is to maintain adequate levels of funding to support the acquisition and exploration of resources properties, the advancement of the Company's prospective separation technology, and maintain the necessary corporate and administrative functions to facilitate these activities. This is done primarily through equity and debt-based financings. Future financings are dependent on market conditions, and there can be no assurance the Company will be able to raise funds in the future.

The Company invests all capital that is surplus to its immediate operational needs in a high interest savings account. There were no changes to the Company's approach to capital management during the period. The Company is not subject to externally imposed capital requirements.

6. RECEIVABLES

	June 30, 2023	December 31, 2022
	(\$)	(\$)
Goods and Service Tax / Harmonized Sales Tax	159,935	264,454
SR&ED tax credit receivable	301,312	169,057
Total	461,247	433,511



6. RECEIVABLES (continued)

SR&ED credits are recorded as a cost recovery against research and development and the Company's Pilot Plant (note 7). During the six-month period ended June 30, 2023, the Company recorded a cost recovery receivable to research and development and the Company's pilot plant of \$Nil (December 31, 2022 - \$56,037) and \$132,255 (December 31, 2022 - \$113,020) respectively.

7. PLANT AND EQUIPMENT

	04:	Cyploretics	Dagage	Dilet	Strategic	
	Office	Exploration	Research	Pilot	Metals	Tatal
	Equipment	Equipment	Equipment	Plant ⁽²⁾	Complex ⁽³⁾	Total
	(\$)	(\$)	(\$)	(\$)	(\$)	(\$)
Cost						
Balance, January 1, 2022	256,330	142,746	67,043	-	-	466,119
Additions ⁽¹⁾	5,718	-	1,516	2,363,022	-	2,370,256
Balance, December 31, 2022	262,048	142,746	68,559	2,363,022	-	2,836,375
Additions ⁽¹⁾	-	-	-	2,321,951	227,023	2,548,974
Balance, June 30, 2023	262,048	142,746	68,559	4,684,973	227,023	5,385,349
Accumulated amortization						
Balance, January 1, 2022	234,129	140,941	18,114	-	-	393,184
Amortization	7,688	108	32,964	-	-	40,760
Balance, December 31, 2022	241,817	141,049	51,078	-	-	433,944
Amortization	3,213	38	11,139	-	-	14,390
Balance, June 30, 2023	245,030	141,087	62,217	-	-	448,334
Net book value						
Balance, December 31, 2022	20,231	1,697	17,481	2,363,022	-	2,402,431
Balance, June 30, 2023	17,018	1,659	6,342	4,684,973	227,023	4,937,015

⁽¹⁾ Additions to the Pilot Plant during the six-month period ended June 30, 2023 were reduced by a SR&ED recovery of \$132,255 (December 31, 2022 - \$113,020).

8. RIGHT OF USE ASSET

The Company recognized a right-of-use asset for the lease of the Company's head office located in Bedford, Nova Scotia. The discount rate applied to the lease is 15%.

Cost	(\$)
Balance, December 31, 2021	416,201
Additions	-
Balance, December 31, 2022	416,201
Additions	-
Balance, June 30, 2023	416,201
Depreciation	
Balance, December 31, 2021	253,650
Charge for the year	88,664
Balance, December 31, 2022	342,314
Charge for the period	44,332
Balance, June 30, 2023	386,646
Net book value	
Balance, December 31, 2022	73,887
Balance, June 30, 2023	29,555

Depreciation of right-of-use assets is calculated using the straight-line method over the remaining lease term.



⁽²⁾ Amortization of the Pilot Plant will commence when the Pilot Plant is available for use which will occur once it has been commissioned.

⁽³⁾ Amortization of the Strategic Metals Complex will occur once it has been fully constructed and available for use.

9. INTELLECTUAL PROPERTY

On May 8, 2020, the Company acquired 100% of the issued and outstanding shares of Innovation Metals Corp. ("IMC"), a company focused on research and development of technologies for the separation of critical metals including rare earth elements, pursuant to the terms and conditions set forth in a share purchase agreement dated April 27, 2020. Management has assessed the acquisition of IMC to be an asset acquisition due to the concentration test. As part of the acquisition, the Company acquired intellectual property with a value of \$8,089,154. The following table reconciles the changes attributable to the Company's intellectual property:

	December 31, 2022 (\$)	Additions (\$)	Amortization (\$)	June 30, 2023 (\$)
Intellectual property	8,089,154	-	-	8,089,154
	December 31, 2021	Additions	Amortization	December 31, 2022
	(\$)	(\$)	(\$)	(\$)
Intellectual property	8,089,154	-	-	8,089,154

Amortization of the intellectual property will commence when the assets are available for commercial production. Until this occurs the Company tests the intellectual property for impairment annually by comparing the carrying value to the recoverable amount, being the greater of the value in use or the fair value less costs of disposal.

10. RESOURCE PROPERTIES AND RELATED EXPLORATION COSTS

The Company's interest in resource properties and related exploration costs consist of the following:

	December 31, 2022 (\$)	Deferred exploration costs (\$)	Movement in exchange rates (\$)	June 30, 2023 (\$)
Bokan Mountain, Alaska	39,673,847	112,851	(524,750)	39,261,948
	December 31, 2021 (\$)	Deferred exploration costs (\$)	Movement in exchange rates (\$)	December 31, 2022 (\$)
Bokan Mountain, Alaska	37,205,010	767,216	1,701,621	39,673,847

The Company holds the exclusive right to acquire up to a 100% interest in the Bokan Mountain rare earth element property, subject to certain royalties. The Company holds a 100% interest in five separate option agreements to acquire a 100% interest in a parcel of unpatented mineral claims from underlying owners and staked a 100% interest in an additional parcel of prospective ground.

The option agreements provide for the Company to acquire a 100% interest in the optioned claims in exchange for total remaining payments of US\$90,000. The five vendors will retain Net Smelter Royalties ("NSR") ranging from 2% to 4% on their specific claims. The Company has the right to purchase between 33% and 100% of the NSR for cash payments of US\$500,000 to US\$1,000,000 per vendor.

11. LEASE LIABILITIES

In February 2012, the Company entered into a five-year operating lease for its head office premises in Halifax, Nova Scotia which began in October 2012. This lease was extended until October 2020 and further extended to October 2023. The Company is required to make monthly lease payments of \$9,221 per month until the expiration of the lease. The Company's subsidiary, IMC, entered into a research facility lease in Kingston, Ontario in June 2020 which either party can terminate with 60 days' notice.



11. LEASE LIABILITIES (continued)

The following table reconciles the changes attributable to the Company's finance lease obligations:

	June 30, 2023	December 31, 2022
	(\$)	(\$)
Balance, beginning of period	87,250	178,603
Additions	-	-
Lease payments	(55,325)	(110,649)
Finance expense	4,280	19,296
Balance, end of period	36,205	87,250
Current portion	36,205	87,250
Non-current portion	-	-
Balance, end of period	36,205	87,250

12. LOANS PAYABLE

a) Orca Term Loan

On November 29, 2021, the Company renegotiated a term loan in the amount of \$1,230,283 (\$964,928 USD) with Orca Holdings, LLC ("Orca") a related party, extending the maturity date by 24 months to November 30, 2023 and in conjunction with the extension the Company issued 1,000,000 share purchase warrants to Orca. Each share purchase warrant entitled Orca to acquire one common share of the Company at an exercise price of \$1.20 to November 30, 2023. The term loan had an interest rate of 9%.

The amendment was treated as an extinguishment and creation of a new debt instrument as the amendments resulted in a substantive change to the loan agreement. The effective interest rate used to determine the fair value of the amended loan for initial recognition was 15%. The fair value of the warrants was determined to be \$403,063 using the Black-Scholes option pricing model using the following assumptions: risk-free interest rate – 0.95%, expected life – 2.00 years, expected annual volatility – 108%, expected dividends – Nil.

On December 18, 2022, the Company renegotiated the Orca Term Loan extending the maturity date to November 30, 2024. A total of 1,000,000 warrants previously issued to Orca in connection with the original Orca Term Loan were cancelled concurrently with the execution of the amendment. As consideration for the extension of the maturity date the Company issued 1,000,000 warrants with each warrant entitling Orca to acquire one common share of the Company at an exercise price of \$0.85 for a period ending on November 30, 2024. The renegotiated Orca Term Loan has an interest rate of 9%.

The amendment was treated as a modification of the remaining principal owing as the modifications to the existing terms did not result in a substantive change in the loan agreement. The remaining portion of the loan that was modified resulted in a gain on modification of \$64,609. The fair value of the warrants was determined to be \$282,641 using the Black -Scholes option pricing model using the following assumptions: risk-free interest rate – 3.66%, expected life – 1.95 years, expected annual volatility – 79.19%, expected dividends – Nil, expected forfeiture rate – Nil.

b) 2022 Orca LOC

On July 20, 2022, the Company entered into a secured line of credit facility (the "2022 Orca LOC"), with Orca, in the amount of \$2,574,984 (\$2,000,000 USD) with an interest rate of 9%. In consideration for granting the 2022 Orca LOC, the Company issued 2,000,000 warrants to Orca. Each warrant entitled Orca to acquire one common share of the Company at an exercise price of \$0.75 for a period of one-year ending on July 20, 2023.

The 2022 Orca LOC had an interest rate of 9% annually and any drawdowns are to be made in multiples of \$100,000 USD. All amounts owing under the 2022 Orca LOC were repayable on January 20, 2023. In the event that the Company completed an equity financing for net proceeds exceeding \$3,000,000 USD the maturity date of the 2022 Orca LOC was to accelerate and be set at the date that is five business days subsequent to the final closing date of the equity financing.



12. LOANS PAYABLE (continued)

The fair value of the warrants was determined to be \$219,905 using the Black-Scholes option pricing model with the following assumptions: volatility of 59.56%, an expected life of 1 year, risk free rate of 3.30%, and expected dividends – Nil. The fair value of the warrants issued in connection with the 2022 Orca LOC represented a deferred financing fee which was amortized through profit or loss over the term of the 2022 Orca LOC.

On December 18, 2022, the Company amended the 2022 Orca LOC agreement, where by a total of \$850,000 USD was repaid by December 30, 2022 and the maturity date for the remaining \$1,150,000 USD was extended to March 31, 2024. A total of 1,150,000 warrants previously issued to Orca in connection with the original 2022 Orca LOC were cancelled concurrently with the execution of the amendment. As consideration for not requiring the full repayment of the line of credit and the extension of the maturity date the Company issued 1,150,000 warrants with each warrant entitling Orca to acquire one common share at an exercise price of \$0.75 for a period ending on March 31, 2024. The amended 2022 Orca LOC has an interest rate of 9%. The effective interest rate used to determine the fair value of the amended 2022 Orca LOC for initial recognition was 15%.

The amendment was treated as a modification of the remaining principal owing as the modifications to the existing terms did not result in a substantive change in the loan agreement. The remaining portion of the loan that was modified resulted in a gain on modification of \$131,983. The fair value of the warrants was determined to be \$240,419 using the Black -Scholes option pricing model using the following assumptions: risk-free interest rate – 3.66%, expected life – 1.28 years, expected annual volatility – 65.21%, expected dividends – Nil, expected forfeiture rate – Nil.

c) 2023 Orca LOC

On May 9, 2023, the Company entered into a secured line of credit facility (the "2023 Orca LOC"), with Orca, in the amount of \$1,345,005 (\$1,000,000 USD) with an interest rate of 10%. An administrative loan origination fee equal to 1.5% of the available 2023 Orca LOC will be paid at maturity. In consideration for granting the 2023 Orca LOC, the Company issued 1,000,000 warrants to Orca. Each warrant entitled Orca to acquire one common share of the Company at an exercise price of \$1.20 for a period of one-year ending on May 9, 2024. Any drawdowns are to be made in multiples of \$100,000 USD. All amounts owing under the 2023 Orca LOC are repayable by December 31, 2023.

The fair value of the warrants was determined to be \$330,087 using the Black-Scholes option pricing model with the following assumptions: volatility of 77.05%, an expected life of 1 year, risk free rate of 3.80%, and expected dividends – Nil. The fair value of the warrants issued in connection with the 2023 Orca LOC represented a deferred financing fee which will be amortized through profit or loss over the term of the 2023 Orca LOC.

The following table summarizes the advances, repayments, loan amendments and amounts owing under the Orca Term Loan, 2022 Orca LOC, and the 2023 Orca LOC:

	2023 Orca	2022 Orca	Orca Term	Total
	LOC	LOC	Loan	(\$)
	(\$)	(\$)	(\$)	
Balance, December 31, 2021	-	-	1,103,025	1,103,025
Additions	-	2,628,142	-	2,628,142
Repayment	-	(1,153,822)	-	(1,153,822)
Deferred financing fees	-	(240,419)	(282,641)	(523,060)
Loss on loan restructuring	-	(131,983)	(64,609)	(196,592)
Interest and accretion expense	-	86,039	63,819	149,858
Foreign exchange	-	97,445	79,519	176,964
Balance, December 31, 2022	-	1,285,402	899,113	2,184,515
Additions	1,345,005	-	-	1,345,005
Interest and accretion expense	19,197	193,044	84,352	296,592
Foreign exchange	(20,344)	(29,803)	(21,010)	(71,157)
Balance, June 30, 2023	1,343,858	1,448,643	962,455	3,754,956

The loan balance is secured by a first charge on the Company's assets.



13. CONVERTIBLE DEBENTURES

On May 21 and May 29, 2020, the Company issued 1,280 and 1,520 respectively, of convertible debentures, with a face value of \$1,000 each for total gross proceeds of \$2.8 million. As at June 30, 2023, 1,255 convertible debentures remain outstanding. The convertible debentures bear interest of 7.5% payable semi-annually and the principal amount originally matured on May 31, 2023. On May 31, 2023, the Company exercised an option to extend the term to May 31, 2024. As a result of the election to extend the term the Company paid an extension fee to the debenture holders in an amount equal to six months interest and recorded a gain on the extension of the convertible debentures of \$167,574. The debenture holder has the right at any time on or prior to the maturity date to convert all or any portion of the outstanding principal into units of the Company at a conversion price of \$1.20 per unit. Each unit is comprised of one common share and one-half of one common share purchase warrant.

Each whole warrant is exercisable by the holder to purchase one common share at an exercise price of \$1.80 per common share, exercisable until the maturity date of the debenture. Should the common shares of the Company trade at a closing price of \$2.20 per common share or higher on the TSX Venture Exchange for twenty consecutive trading days, the debentures shall automatically convert into units at a conversion price of \$1.20 per unit.

In conjunction with the convertible debenture offering, the Company issued 140,000 commitment warrants. Each warrant entitled the holder to acquire one common share at an exercise price of \$1.80 per common share prior to May 31, 2022.

For accounting purposes, the debentures represent a hybrid financial instrument, consisting of a host loan obligation, and embedded derivative instruments comprising the conversions, extension and early conversion features of the debenture. The Company accounts for the host loan obligation at amortized cost, accrued to maturity over the term of the debenture. The embedded conversion and extension options are accounted for as a financial liability measured at fair value through profit or loss. The commitment warrants are accounted for as equity.

At the dates of issue, the convertible debentures and its components were measured at fair values, as follows:

	May 21, 2020	May 29, 2020
	Tranche	Tranche
	(\$)	(\$)
Host liability component at issue	813,114	988,160
Conversion and extension options at issue date	555,086	672,096
Fair value of commitment warrants	202,964	244,550
Loss on initial recognition	291,164	384,806
Net proceeds from issue	1,280,000	1,520,000

The following table summarizes the continuity of the host liability components of the loan:

	May 21, 2020	May 29, 2020	
	Tranche	Tranche	Total
	(\$)	(\$)	(\$)
Balance, December 31, 2021	34,898	996,807	1,031,705
Accretion on discount	4,259	153,313	157,572
Balance, December 31, 2022	39,157	1,150,120	1,189,277
Accretion on discount	(3,807)	82,484	78,677
Gain on extension of convertible debentures	(4,520)	(163,054)	(167,574)
Balance, June 30, 2023	30,830	1,069,550	1,100,380



13. CONVERTIBLE DEBENTURES (continued)

The following table summarizes the continuity of the conversion option components of the loan:

	May 21, 2020	May 29, 2020	
	Tranche	Tranche	Total
	(\$)	(\$)	(\$)
Balance, December 31, 2021	5,575	194,329	199,904
Fair value adjustment	(186)	(132,306)	(132,492)
Balance, December 31, 2022	5,389	62,023	67,412
Fair value adjustment	1,760	186,231	187,991
Balance, June 30, 2023	7,149	248,254	255,403

The fair value of the conversion options outstanding has been determined using a binomial option valuation model, using the following key assumptions:

	Trance 1 - May 21, 2020		Trance 2 – Ma	y 29, 2020
	June 30,	June 30, December 31,		December 31,
	2023	2022	2023	2022
Expected volatility	78%	61%	78%	61%
Risk-free interest rate	4.93%	4.41%	4.93%	4.41%
Conversion option term	0.89 years	0.39 years	0.91 years	0.41 years
Credit spread	21.00%	21.00%	21.00%	21.00%
Underlying share price	\$0.97	\$0.75	\$0.97	\$0.75

14. SHARE CAPITAL

Authorized:

Unlimited number of common voting shares

Unlimited number of first preferred non-voting shares issuable in series

Unlimited number of second preferred non-voting share issuable in series

a) Financing

On December 22, 2022, the Company closed a non-brokered private placement which consisted of an aggregate of 7,7055,795 units at a subscription price of \$0.65 per unit for aggregate gross proceeds to the Company of \$4,586,267. Each unit consists of one common share of the Company and one common share purchase warrant. Each warrant entitles the holder thereof to acquire one additional common share at a price of \$0.85 per share for a period of 24 months from the date of issuance.

The Company determined that the fair value of the warrants issued was \$1,996,134. The fair value was determined using the Black-Scholes option pricing model using the following assumptions: volatility of 79.95%, an expected life of 2 years, risk free rate of 3.82%, and a zero expected dividend yield.

The Company paid finder's fees totaling \$24,115 and issued a total of 370,140 finder's warrants pursuant to certain subscriptions. Each finder's warrant issued entitles the holder to acquire one common share at a price of \$0.65 per share for a period of 24 months from the date of issuance. The Company determined that the fair value of the finder's warrants issued was \$124,863. The fair value was determined using the Black-Scholes option pricing model using the following assumptions: volatility of 79.95%, an expected life of 2 years, risk free rate of 3.82%, and a zero expected dividend yield. Other costs associated with the private placement totalled \$116,463 for total costs of \$140,578. The following is a summary of the allocated of proceeds and costs between common shares and warrants.

	Allo	Allocation of proceeds			
	Shares (\$)	Warrants (\$)	Total (\$)		
Proceeds	2,590,133	1,996,134	4,586,267		
Cash costs	(79,393)	(61,185)	(140,578)		
Finder's warrants	(70,518)	70,518	-		
Closing balance	2,440,222	2,005,467	4,445,689		



14. SHARE CAPITAL (continued)

b) Stock Options and Deferred Share Units

For the six-month period ended June 30, 2023, the Company recognized share-based compensation expense of \$794,981 (June 30, 2022 - \$173,700) for options granted to directors, employees, and consultants of which \$33,121 (June 30, 2022 - \$Nil) was capitalized to the Company's Pilot Plant. During the six-month period ended June 30, 2022, the Company recorded a forfeiture recovery to share based compensation expense of \$62,248. As a result of the transactions during the period \$761,860 (June 30, 2022 - \$111,452) was charged to net loss.

Changes in stock options during the six-month period ended June 30, 2023 and year ended December 31, 2022 are summarized below:

		Year ended December 31, 2022		
	Number of options	Weighted average exercise price (\$)	Number of options	Weighted average exercise price (\$)
Opening balance	3,594,000	1.02	2,329,000	1.81
Granted	1,635,000	1.32	3,250,000	0.85
Expired	(20,000)	1.90	(810,000)	2.65
Forfeited	-	-	(250,000)	1.41
Closing balance	5,209,000	1.11	3,594,000	1.02
Weighted average remaining life		3.88 years		3.95 years

On March 6, 2023, the Company granted 210,000 options to consultants of the Company and on April 11, 2023, the Company granted 1,425,000 options to consultants and employees of the Company. The fair value of options granted during the six-month period ended June 30, 2023 has been estimated using the Black-Scholes option pricing model. The weighted average assumptions used in the pricing model for options granted during the six-month period ended June 30, 2023 and December 31, 2022, are as follows:

	June 30,	December 31,	
	2023	2022	
	(\$)	(\$)	
Risk-free interest rate	3.13%	2.91%	
Expected life of each option	3 years	3 years	
Expected volatility	87%	101%	
Expected dividends	Nil	Nil	
Weighted average grant date fair value	\$0.76	\$0.54	
Rate of forfeiture	0.00%	0.00%	

The following table summarizes information about the stock options outstanding and exercisable at June 30, 2023:

Exercise price per share	Number of options		Number of exercisable
(\$)	outstanding	Expiry date	(vested) options
0.85	2,325,000	August 9, 2027	775,000
1.20	120,000	May 17, 2026	120,000
1.20	384,000	November 15, 2024	384,000
1.30	480,000	September 1, 2026	480,000
1.30	20,000	March 26, 2026	20,000
1.30	1,425,000	April 11, 2028	-
1.45	210,000	March 6, 2028	-
1.55	40,000	September 23, 2024	40,000
1.65	185,000	May 15, 2025	185,000
2.30	20,000	July 30, 2023	20,000
	5,209,000		2,024,000
Weighted average			
remaining life			3.88 years



14. SHARE CAPITAL (continued)

As at June 30, 2023, there are 55,710 (December 31, 2022 – 55,710) deferred share units outstanding which been fully vested.

c) Warrants

Changes in share purchase warrants during the six-month period ended June 30, 2023 and year ended December 31, 2022 are summarized as follows:

		Period ended June 30, 2023			
	Number of	Weighted average	Number of	Weighted average	
	warrants	exercise price (\$)	warrants	exercise price (\$)	
Opening balance	14,684,075	1.02	5,393,140	1.46	
Granted	1,000,000	1.20	11,575,935	0.82	
Cancelled	-	-	(2,150,000)	0.96	
Exercised	(7,000)	0.65	-	-	
Expired	(602,080)	1.80	(135,000)	1.80	
Closing balance	15,074,995	1.00	14,684,075	1.02	
Weighted average remaining life		1.09 years		1.55 years	

The fair value of warrants granted has been estimated using the Black-Scholes option pricing model. The weighted average assumptions used in the pricing model for the warrants granted during each period are provided below.

	June 30, 2023	December 31, 2022
	(\$)	(\$)
Risk-free interest rate	3.80%	3.70%
Expected life	1.00 year	1.75 years
Expected volatility	77%	75%
Expected dividends	Nil	Nil

During the six-month period ended June 30, 2023, warrants issued in connection with the exercise of the Company's convertible debentures expired unexercised. This resulted in a decrease to warrants and an increase to contributed surplus of \$603,361. During the year ended December 31, 2022, warrants from financings completed in 2020 expired unexercised. This resulted in a decrease to warrants and an increase to contributed surplus of \$445,928. During the year ended December 31, 2022, the Company amended the terms of the Orca Loan and the Orca Line of Credit and a result of the amendments the Company cancelled 2,150,000 warrants resulting in a decrease to warrants and an increase to contributed surplus of \$529,509. The following table summarize information about the warrants outstanding and exercisable at June 30, 2023:

Exercise price per share		
(\$)	Expiry date	Number of warrants
0.65	December 22, 2024	363,140
0.75	July 20, 2023	850,000
0.75	March 31, 2024	1,150,000
0.85	November 30, 2024	1,000,000
0.85	December 22, 2024	7,055,795
1.00	February 8, 2024	306,060
1.20	May 9, 2024	1,000,000
1.50	February 8, 2024	3,350,000
		15,074,995
Weighted average remaining life		1.09 years

On July 20, 2023, the Company received \$637,500 from Orca Holdings, LLC for the exercise of 850,000 warrants.



15. RELATED PARTY TRANSACTIONS

Related parties consist of key management personnel, directors, and entities that are associated with the Company as well as significant shareholders, including Orca Holdings, LLC ("Orca") which is owned by Mr. Randy Johnson, a director of the Company. The Company has defined key management personnel as senior executive officers, as well as the Board of Directors. The total remuneration of key management personnel and the Board of Directors was as follows:

	Six month period ended	Six month period ended
	June 30, 2023	June 30, 2022
	(\$)	(\$)
Director's fees	109,500	109,500
Share-based payments to directors	250,254	47,022
Key management short-term benefits	243,108	238,544
Share-based payments to key management	221,072	37,618
· · ·	823.934	432,684

Key management short-term benefits include all salary, bonuses, and health/dental benefits earned by officers during the period. During the six-month period ended June 30, 2023, the Company paid \$216,817 (Q2 2022 - \$171,151) in legal fees to Miller Thomson LLP. Mr. Geoff Clarke, a director of the Company, is a partner of that law firm. Payments made by the Company to Miller Thomson LLP are for the various legal services provided to the Company by several lawyers and law clerks at the firm, which includes lawyers and law clerks in multiple provinces and offices across Canada.

For additional related party transactions see note 12, 14, and 19.

16. FINANICAL INSTRUMENTS AND RISK MANAGEMENT

Assets and liabilities measured at fair value in the consolidated financial statements are classified into one of three levels in the fair value hierarchy according to the relative reliability of the inputs used to estimate fair values. The three levels of fair value hierarchy are:

- Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities;
- Level 2 Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly: and
- Level 3 Inputs that are not based on observable market data.

The fair value hierarchy of assets and liabilities measured at fair value of the consolidated statements of financial position are disclosed in the notes to the financial statements is as follows:

	J	June 30, 2023			cember 31, 2	022
Financial assets:	Level 1	Level 2	Level 3	Level 1	Level 2	Level 3
Marketable securities (\$)	750	-	-	1,500	-	-
Financial liabilities: Convertible debenture –						
conversion option (\$)	-	(255,403)	-	-	(64,412)	-

Liquidity Risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with the financial liabilities that are settled by delivering cash or another financial asset.

The Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due and to continue to fund its exploration and evaluation activities, and advance the Company's RapidSXTM technology. The Company's accounts payable and accrued liabilities are due within six months. Their contractual cash flow is equal to their carrying value. Short term deposits are held in interest bearing instruments that can be converted to cash without penalty at any time and are recorded at fair value.



16. FINANICAL INSTRUMENTS AND RISK MANAGEMENT (continued)

The following are the contractual maturities of the financial liabilities and other commitments. The table includes undiscounted cash flows of financial liabilities, including lease liabilities and other commitments, interest and principal cash flows based on the earliest date on which the Company is required to pay.

		Total						
	Carrying	contractual						
	amount	cash flows	2023	2024	2025	2026	2027	>2027
June 30, 2023	(\$)	(\$)	(\$)	(\$)	(\$)	(\$)	(\$)	(\$)
Interest- lease								
liabilities	-	677	677	-	-	-	-	-
Principal repayments								
 lease liabilities 	36,205	36,205	36,205	-	-	-	-	-
Interest – convertible								
debentures	-	94,383	47,191	47,191	-	-	-	-
Principal – convertible								
debentures	1,255,000	1,255,000	-	1,255,000	-	-	-	-
Interest – loans								
payable	-	331,073	124,308	206,766	-	-	-	-
Principal repayments								
 loans payable 	4,126,594	4,126,594	1,324,780	2,801,814	-	-	-	-
	5,417,799	5,843,932	1,533,161	4,310,771	-	-	-	
Trade and other								
payables	2,861,340	2,861,340	2,861,340	-	-	-	-	-
	8,279,139	8,705,272	4,394,501	4,310,771	-	-	-	-

Market Risk

Market risk is the risk of loss that may arise from changes in market factors such as foreign currency rates, interest rates, and commodity and equity prices.

Foreign Currency Risk

A significant portion of the Company's transactions occur in United States dollars and accordingly, the related financial assets and liabilities are subject to fluctuations in the respective exchange rates. To limit exposure to this risk, cash and short-term investments are primarily held with high quality financial institutions in Canada.

The Company's exposure to US dollar currency risk as measured in Canadian dollars was as follows:

	June 30, 2023	December 31, 2022
	(\$)	(\$)
Cash	52,196	311,897
Other asset	67,829	69,328
Accounts payable	(430,088)	(146,062)
Loans payable	(3,754,955)	(2,184,515)
	(4,065,018)	(1,949,352)

A 10% change in the US dollar exchange rate would affect net and comprehensive loss and deficit by \$406,502 (2022 - \$194,935).

Interest Rate Risk

From time to time the Company holds cash in a high interest savings account. The Company does not have any debt that bears variable interest rates.



17. SUPPLEMENTARY CASH FLOW INFORMATION

	June 30, 2023	June 30, 2022
	(\$)	(\$)
Non-cash financing and investing activities:		
Accounts payable and accrued liabilities related to resource		
properties and related exploration costs	(19,542)	504,899
Accounts receivable related to Pilot Plant	301,313	-
Accounts payable related to Pilot Plant	915,309	-
Prepaids related to resource properties and related exploration		
costs	(75,348)	3,570
Share based payments related to Pilot Plant	33,121	-
Reversal of reserves relating to the expiration of warrants	603,361	431,828
Reversal of reserves relating to the exercise of warrants	2,361	-
Warrants issued in connection with loans payable	330,087	-

18. CONTINGENCY

On December 14, 2022, a former employee of IMC filed a civil claim against IMC and Ucore for wrongful dismissal and breach of contract. The claim is derived from an employment relationship between the former employee and IMC and the subsequent termination of this relationship. The Company believes that the action is without merit and intends to fully defend its interest and take all other legal actions available to it. The outcome of this claim cannot be determined at this time and no provision has been made in the condensed interim consolidated financial statements for the six-month period ended June 30, 2023.

19. SUBSEQUENT EVENTS

Private Placement Financing of Units

On July 27, 2023, the Company closed the first of two tranches of a private placement offering of units of the Company, pursuant to which the Company issued 4,409,500 units at a price of \$1.00 per unit for aggregate gross proceeds of \$4,409,500 (the "First Tranche"). On July 28, 2023, the Company closed the second and final tranche of its private placement offering of units of the Company, with the second tranche consisting of 413,000 units at a price of \$1 per unit for additional gross proceeds of \$413,000 (the "Second Tranche"). In total the Company raised an aggregate of \$4,822,500 from the offering through the issuance of 4,822,500 units.

Each unit is comprised of one common share in the capital of the Company (each, a "Common Share") and one-half of one Common Share purchase warrant (each whole warrant, a "Warrant"). Each Warrant entitles the holder to purchase one Common Share at an exercise price of \$1.25 per Common Share for a period of 36 months following the closing date of the First Tranche and the Second Tranche.

The brokered portion of the private placement offering of units was lead by a syndicate of agents (collectively, the "Agents"). In connection with the First Tranche, the Agents received an aggregate cash fee equal to \$192,790. In addition, the Company issued to the Agents 192,790 non-transferable compensation options (the "Compensation Options"). Each Compensation Option entitles the holder thereof to purchase one Unit at an exercise price equal to the Offering Price for a period of 36 months following the date of the closing of the First Tranche.

In addition, pursuant to an advisory agreement between the parties, the Company has also paid the Agents an advisory fee of \$27,765, plus applicable taxes. In addition, the Agents received 27,765 advisory fee Compensation Options to purchase an equal number of Units, subject to adjustment in certain circumstances, at the Offering Price for a period of 36 months following the date of issue.

Insiders of the Company purchased a total of 220,000 units for gross proceeds to the company of approximately \$220,000.

The Company plans to use the net proceeds of the Offering for the following: (i) completing the commission trials at the Company's RapidSXTM rare earth element ("REE") commercial demonstration plant located in Kingston, Ontario (the "Demo Plant"); and (ii) working capital purposes.



Notes to Condensed Interim Consolidated Financial Statements For the six-month period ended June 30, 2023

(Unaudited – Prepared by Management) (Expressed in Canadian dollars)

19. SUBSEQUENT EVENTS (continued)

Exercise of Warrants

On July 20, 2023, the Company received \$637,500 from Orca Holdings, LLC for the exercise of 850,000 warrants.

